Your browser doesn't support javascript.
Favipiravir for the treatment of COVID-19 pneumonia: Can we predict the response to treatment?
Sayiner, Abdullah; Erdem, Huseyin Aytac; Korkmaz Ekren, Pervin; Tasbakan, Sezai; Basoglu, Ozen K; Tasbakan, Meltem Isikgoz; Yamazhan, Tansu; Gokengin, Deniz; Ozhan, Mustafa Hikmet.
  • Sayiner A; Department of Chest Diseases, Ege University Faculty of Medicine, Izmir, Turkey. sayiner2011@gmail.com.
  • Erdem HA; Department of Infectious Diseases, Ege University Faculty of Medicine, Izmir, Turkey.
  • Korkmaz Ekren P; Department of Chest Diseases, Ege University Faculty of Medicine, Izmir, Turkey.
  • Tasbakan S; Department of Chest Diseases, Ege University Faculty of Medicine, Izmir, Turkey.
  • Basoglu OK; Department of Chest Diseases, Ege University Faculty of Medicine, Izmir, Turkey.
  • Tasbakan MI; Department of Infectious Diseases, Ege University Faculty of Medicine, Izmir, Turkey.
  • Yamazhan T; Department of Infectious Diseases, Ege University Faculty of Medicine, Izmir, Turkey.
  • Gokengin D; Department of Infectious Diseases, Ege University Faculty of Medicine, Izmir, Turkey.
  • Ozhan MH; Department of Chest Diseases, Ege University Faculty of Medicine, Izmir, Turkey.
J Infect Dev Ctries ; 16(3): 422-426, 2022 03 31.
Article in English | MEDLINE | ID: covidwho-1786129
ABSTRACT

INTRODUCTION:

Early experience with favipiravir in the treatment of COVID-19 is promising, but no clinical data have been published in medical journals. This study aimed to review the experience with favipiravir treatment for COVID-19 pneumonia and to examine whether there are any predictors of treatment response.

METHODOLOGY:

Fifty-six patients with severe or progressive pneumonia associated with COVID-19 who were treated with favipiravir monotherapy for at least five days were included in this retrospective study. Treatment response was defined as clinical recovery without any need for admission into the intensive care unit and/or anti-cytokine therapy. The demographic, clinical, laboratory and radiographic features of the patients were compared between favipiravir-responders and non-responders.

RESULTS:

Of the 56 patients, 34 patients (60.7%) responded to treatment and recovered. There was no difference in the demographic, clinical, and radiographic findings between the responders and non-responders. The inflammatory biomarkers were also similar except for the CRP levels on the day favipiravir was started [74 (36-111) vs. 118.5 (46.5-203) mg/L, respectively, p = 0.043]. There was also a significant difference in the median time to defervescence [1 (1-2) vs. 3.5 (1.75-9.25) days, respectively]. Of clinical interest, 27 (79.4%) and 31 (91.2%) of the responders became afebrile within two and four days, respectively. The response rate was lower in patients who presented severe pneumonia associated with respiratory failure.

CONCLUSIONS:

Patients with non-severe pneumonia at admission and whose fever resolved within two days of treatment are more likely to improve with favipiravir.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: J Infect Dev Ctries Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Jidc.14033

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: J Infect Dev Ctries Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Jidc.14033